Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that affects white blood cells called lymphocytes. There are many types of leukemia, and CLL is a common type in adults. This type of ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different types of leukemia. Both conditions affect white blood cells. CML affects a type of white blood cell called ...

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients. The treatment of chronic lymphocytic leukemia (CLL) has evolved ...

A phase 3, randomized, open-label trial enrolled 535 patients who were randomly assigned 1:1:1 to receive acalabrutinib-obinutuzumab (n = 179), acalabrutinib monotherapy (n = 179), or ...

In this video, Matthew S. Davids, MD, said data from the BRUIN-313 trial supports front-line approval of pirtobrutinib in patients with previously untreated chronic lymphocytic leukemia or small ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...